2010•Unpublished venueRequires access

Clinical efficacy of pioglitazone combined with metformin in type 2 diabetes patients

Shengwei Yang

Open publisher page 0 citations

Abstract

Objective To observe the effects of pioglitazone combined with metformin in type 2 diabetes.Methods 152 type 2 diabetes patients were randomly divided into control group and treatment group.The control group was treated with metformin 0.5g,3 time every day.The treatment group received pioglitazone 30mg,one time every day,except took metformin 0.5 g,3 time every day.Two groups all completed a therapeutic period of 3 months.Results The effect of the treatment group compared with the control group has significantly statistical difference(P<0.05).Fasting blood glucose and postprandial blood glucose:compared back and forth,the treatment group and control group all have significantly statistical difference(all P<0.05);the result of the treatment group compared with that of the control group has significant difference also(all P<0.05).Conclusion The therapeutic effect of pioglitazone combined with metformin on type 2 diabetes patients was much better than metformin only. Key words: Diabetes,type 2; Pioglitazone; Metformin

About this research paper

What this paper is about

Objective To observe the effects of pioglitazone combined with metformin in type 2 diabetes.Methods 152 type 2 diabetes patients were randomly divided into control group and treatment group.The control group was treated with metformin 0.5g,3 time every day.The treatment group received pioglitazone 30mg,one time every day,except took metformin 0.5 g,3 time every day.Two groups all completed a therapeutic period of 3 months.Results The effect of the treatment group compared with the control group has significantly statistical difference(P<0.05).Fasting blood glucose and postprandial blood glucose:compared back and forth,the treatment group and control group all have significantly statistical difference(all P<0.05);the result of the treatment group compared with that of the control group has significant difference also(all P<0.05).Conclusion The therapeutic effect of pioglitazone combined with metformin on type 2 diabetes patients was much better than metformin only. Key words: Diabetes,type 2; Pioglitazone; Metformin

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To observe the effects of pioglitazone combined with metformin in type 2 diabetes.Methods 152 type 2 diabetes patients were randomly divided into control group and treatment group.The control group was treated with metformin 0.5g,3 time every day.The treatment group received pioglitazone 30mg,one time every day,except took metformin 0.5 g,3 time every day.Two groups all completed a therapeutic period of 3 months.Results The effect of the treatment group compared with the control group has significantly statistical difference(P<0.05).Fasting blood glucose and postprandial blood glucose:compared back and forth,the treatment group and control group all have significantly statistical difference(all P<0.05);the result of the treatment group compared with that of the control group has significant difference also(all P<0.05).Conclusion The therapeutic effect of pioglitazone combined with metformin on type 2 diabetes patients was much better than metformin only. Key words: Diabetes,type 2; Pioglitazone; Metformin

Key concepts: Pioglitazone, Metformin, Medicine, Postprandial, Type 2 diabetes, Internal medicine, Diabetes mellitus, Significant difference

Related papers

Back to paper searchBrowse research topicsOriginal source
Clinical efficacy of pioglitazone combined with metformin in type 2 diabetes patients — Research Paper | ScholarLens